MEDIRAD recommendations to enhance the protection of patients and staff exposed to low doses of radiation
MEDIRAD is a research project funded by EURATOM under Horizon 2020 Programme with the overall aim of enhancing the scientific basis and clinical practice of radiation protection in medicine, in particular by better understanding and evaluating the health effects of exposure to low-dose ionising radiation resulting from diagnostic and therapeutic procedures. MEDIRAD brought together radiological and clinical research teams from 14 European countries in order to enhance the scientific knowledge and improve the radiation protection of patients and staff in the clinics.
MEDIRAD launches a series of recommendations to enhance the protection of patients and staff exposed to low doses of radiation
The science-based recommendations draw from research conducted throughout the EU-funded project and from a sustained dialogue with over 80 stakeholder organisations
X-rays, mammographies, CT scans, fluoroscopy, radiotherapy…. Many of us have surely undergone one or more of these medical procedures to diagnose or treat certain health conditions. They all have one thing in common: they use ionising radiation (i.e. radiation that has enough energy to remove an electron from an atom). Although the clinical benefits of these procedures greatly outweigh the risks, it is becoming increasingly important to better understand and evaluate the long-term health effects of exposure to low levels of ionising radiation resulting from these medical applications.
This is what MEDIRAD, an EU-funded research project, aimed to do. “We brought together radiological and clinical research teams from 14 European countries in order to enhance the scientific knowledge and improve the radiation protection of patients and staff in the clinics,” explains Elisabeth Cardis, researcher at ISGlobal, Spain, and scientific coordinator of the project.
“MEDIRAD was designed to have direct impact on the radiological safety of European patients undergoing radiation-based medical procedures,” adds MEDIRAD clinical coordinator Guy Frija, from the Université Paris Descartes, France.
During almost five years, the 34 project partners worked on three main areas. First, improve the way radiation doses delivered to different organs are estimated and registered, in order to optimise the benefit to risk ratio of these procedures. Second, better evaluate and understand the effects of medical exposure to radiation, focusing on two procedures of public health relevance: breast cancer patients treated with radiotherapy and children undergoing CT scans. Third, develop science-based policy recommendations for the effective protection of patients and medical workers. This process involved a constant dialogue between project researchers and over 80 stakeholders from different international and European organisations, who, through two surveys and two webinars, helped define needs and priorities in the field and provided feedback on the recommendations.
Recommendations on four major topics
The priorities were grouped into four major topics: consolidating patient data repositories across Europe; optimising radiation-based protocols for diagnostics and therapy; further optimising radiation protection for patients and staff; and guiding future radiation protection research in Europe.
For each topic, a series of overall recommendations are given, together with an explanation of why they are relevant, how to implement them, and the audiences concerned. The overall message is the need of ‘bringing together’ (data repositories, protocols, disciplines, communities) to optimise existing procedures, foster collaboration and explore new technologies and research avenues.
“Work conducted throughout the project has provided proof of concept on the feasibility of implementing these recommendations,” says Monika Hierath, project coordinator at the European Institute for Biomedical Imaging Research (EIBIR), Austria. “Now we invite the different stakeholders – policy makers, regulators, medical societies, patient associations, clinicians, researchers and industry - to take these recommendations into account for guiding future actions,” she adds.